1Kaufman FR, et al. A pilot study of continuous glucose monitoring system. Diab Care. 2001:24:2030-2034
2Évaluations des utilisateurs. Données Medtronic MiniMed, Inc. en dossier (Northridge, Californie).
3Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in Type 1 diabetes treated with insulin pump therapy: a randomized controlled trial. Diabetologia. 2012;55:3155–3162.
4Doyle EA, Weinzimer SA, Steffen AT, Ahern JAH, Vincent M, Tamborlane WV. A randomized prospective trial comparing the efficacy of insulin pump therapy with multiple daily injections using insulin glargine. Diabetes Care. vol. 27, nᵒ 7 (2004), p. 1554-1558.
5Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycaemia with long-term continuous subcutaneous insulin infusion in Type 1 diabetes. Diabetes Care. 1996;19:324-327.
6The Diabetes Control and Complications Trial Research Group. « The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus ». The New England Journal of Medicine, vol. 329 (1993), p. 977‑986.
7J. C. Pickup and A. J. Sutton Severe hypoglycaemia and glycaemic control in Insulin Dependent Diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion Diabetic Medicine 2008 :25, 765–774.
8Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011 Nov;34(11):2403-5. doi: 10.2337/dc11-1248. Epub 2011 Sep 20.